MIAMI, FL--(MARKET WIRE)--Sep 17, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) (DOR or the Company) announced that a clinical review of its drug orBec® (oral beclomethasone dipropionate, or oral BDP) in the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD) has been published in the peer-reviewed medical journal Expert Review of Clinical Immunology, which reviews clinical results from DOR's two randomized, double-blind, placebo-controlled trials. The author of the review, entitled "Oral Beclomethasone Dipropionate in Gastrointestinal Graft-versus-Host Disease," is David M. Hockenbery, MD, Member of the Clinical Research Division, Fred Hutchinson Cancer Research Center and Professor of Medicine, University of Washington School of Medicine, both located in Seattle, Washington. The full article is available online at www.future-drugs.com.
